Navigation Links
Bausch + Lomb adquirirá Technolas Perfect Vision GmbH
Date:11/7/2012

ROCHESTER, Nueva York, y MÚNICH, 7 de noviembre del 2012 /PRNewswire/ -- Bausch + Lomb, empresa mundial de salud ocular, anunció hoy que ha ejercido su opción para adquirir todas las acciones en circulación y sin titulares de Technolas™ Perfect Vision GmbH (TPV), empresa líder de láser oftalmológico. Technolas Perfect Vision fue creada en el 2009 a través de un acuerdo empresario entre Bausch + Lomb y 20/10 PERFECT VISION AG para desarrollar y vender tecnologías avanzadas refractivas y de cataratas. Se espera que el acuerdo se cierre a fines de enero del 2013.

Bausch + Lomb y Technolas Perfect Vision suscribieron un acuerdo de promoción conjunta en septiembre del 2011, que también incluyó una opción para Bausch + Lomb de adquirir la empresa si se lograban ciertas metas. Desde ese momento, las empresas han aprovechado sus conocimientos refractivos y de cataratas combinados y sus capacidades comerciales para promover y fomentar el láser de femtosegundo VICTUS™, que es capaz de soportar intervenciones de cataratas y de córneas en una sola plataforma. En los últimos doce meses, la plataforma VICTUS recibió la aprobación de comercialización de las autoridades regulatorias de Europa y los Estados Unidos, y las empresas siguen presentando registraciones en otras partes del mundo al tiempo que aceleran la implementación.

"Nuestra adquisición de Technolas Perfect Vision representa un hito importante para Bausch + Lomb, pero tal vez sea más importante marcar lo que significa para los pacientes refractivos y de cataratas de todo el mundo", afirmó Brent Saunders, presidente y director ejecutivo de Bausch + Lomb. "El equipo de Technolas Perfect Vision ha creado una gran empresa y, desde mi perspectiva, los láseres oftálmicos más innovadores del sector".

"Nuestros sis
'/>"/>

SOURCE Bausch + Lomb
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology news :

1. Bausch + Lomb adquiere Technolas Perfect Vision GmbH
2. Bausch + Lomb to Acquire Technolas Perfect Vision GmbH
3. Bausch + Lomb übernimmt Technolas Perfect Vision GmbH
4. Bausch + Lomb prestes a adquirir a Technolas Perfect Vision GmbH
5. Farmers team with scientists to make the perfect rat trap
6. Nutrient and toxin all at once: How plants absorb the perfect quantity of minerals
7. Infrared vision in a cichlid fish
8. New study sheds light on how and when vision evolved
9. Military vision research symposium focuses on visual fallout from war
10. Deep-sea crabs seek food using ultraviolet vision
11. IdentiSys acquires the Identification, Security and Presentation Divisions of Mountainland Business Systems, a Utah based reseller
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... chemical modification of DNA and this modification can ... sequence. Until now, scientists believed that this epigenetic ... Today, a team of researchers from the University ... Louis-Jeantet Professor at the Faculty of Medicine, reveals ... that DNA methylation may play both a passive ...
(Date:6/17/2013)... a new virus in patients with severe brain infections ... the virus is responsible for the symptoms of disease. ... 28 out of 644 patients with severe brain infections ... in any of the 122 patients with non-infectious brain ... and central nervous system are often fatal and patients ...
(Date:6/17/2013)... foundations with more modern elements. Using this same approachbut ... Dietrich School of Arts and Sciences have designed a ... storage, and gas transport more efficient and at a ... issue of the Journal of the American Chemical ... builds upon Pitt Associate Professor of Chemistry Nathaniel Rosi,s ...
Breaking Biology News(10 mins):The secret of DNA methylation 2New virus isolated from patients with severe brain infections 2New virus isolated from patients with severe brain infections 3'Chemical architects' build materials with potential applications in drug delivery and gas storage 2
... 12 collaborating institutions have been awarded $24 million in ... for Environmental Implications of Nanotechnology (UC CEIN), which will ... The center, to be housed ... campus, will explore the impact of nanomaterials on life ...
... DURHAM, NC--The National Science Foundation (NSF) and the Environmental ... the Center for Environmental Implications of NanoTechnology (CEINT) to ... Nanoparticles are as much as a million times smaller ... properties compared with larger objects made from the same ...
... University of North Carolina at Chapel Hill School of Medicine ... insulin, the hormone used to treat diabetes. The ... a cure for the millions of people affected by the ... into pluripotent stem cells, or cells that can give rise ...
Cached Biology News:UCLA, partners establish new center on environmental effects of nanotechnology 2UCLA, partners establish new center on environmental effects of nanotechnology 3UCLA, partners establish new center on environmental effects of nanotechnology 4Duke to lead new NSF, EPA center to study the environmental implications of nanotechnology 2Duke to lead new NSF, EPA center to study the environmental implications of nanotechnology 3UNC scientists turn human skin cells into insulin-producing cells 2
(Date:6/19/2013)... WASHINGTON, D.C. (PRWEB) June 19, 2013 ... with its first Bayer Bee Care Community Leadership Award. ... Pollinator Week Congressional Reception in Washington, D.C., an ... pollinators make to the world’s food supply. , ... who have harnessed the power of the honey bee ...
(Date:6/19/2013)... 19, 2013 BioConvergence team members ... faculty at 2013’s BioLogistics Summit in San Francisco ... by Cold Chain IQ and IQPC, addressed the ... is, in part, attributed to current trends of ... within these trends is an increase in movement, ...
(Date:6/19/2013)... (PRWEB) June 19, 2013 Express Diagnostics ... tests, today announced that it has received Class III ... and sell its DrugCheck® NxStep Onsite Drug Screen ... of the rapid screening device in near-patient settings, such ... Screen Cup received Health Canada Class III approval for ...
(Date:6/18/2013)... China Cord Blood Corporation (NYSE: ... of cord blood collection, laboratory testing, hematopoietic stem cell ... preliminary unaudited financial results for the fourth quarter and ... 2013. Fourth Quarter of Fiscal 2013 ... fiscal 2013 increased by 33.3% to RMB133.0 million ($21.4 ...
Breaking Biology Technology:Community Mentor Wins Inaugural Bayer CropScience Bee Care Leadership Award 2Community Mentor Wins Inaugural Bayer CropScience Bee Care Leadership Award 3Community Mentor Wins Inaugural Bayer CropScience Bee Care Leadership Award 4BioConvergence® Presents at BioLogistics Summit on Risk Matrix for Biosamples during Shipment 2Express Diagnostics’ DrugCheck® On-site Test Cup Receives Health Canada Class III Medical Device Approval 2Express Diagnostics’ DrugCheck® On-site Test Cup Receives Health Canada Class III Medical Device Approval 3China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 2China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 3China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 4China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 5China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 6China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 7China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 8China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 9China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 10China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 11China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 12China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 13
... TROMS0, Norway and SEOUL, Korea, June 19 ... KAEL-GemVax,today announced the signing of a collaborative agreement to ... for the treatment of,cancer. , ... CEO Jay,Sangjae Kim, "We are delighted to announce this ...
... research from Cincinnati Children,s Hospital Medical Center highlights the critical ... embryonic development on formation of a normal heart and skull. ... Proceedings of the National Academy of Sciences , a ... the gene/protein SHP2 interferes with the normal developmental activity of ...
... Inc. (OTC Bulletin Board: GOVX), an Atlanta-based biopharmaceutical ... HIV-1 (Human Immunodeficiency Virus), and other infectious agents, announced ... cooperative arrangement with Cook County Board President Todd H. ... County Health and Hospitals Systems Board ("Health System"); and ...
Cached Biology Technology:Lytix Biopharma and KAEL-GemVax Announce Joint Clinical Trial to Combine LTX-315 and GV1001 Cancer Immunotherapy 2Scientists identify gene vital to early embryonic cells forming a normal heart and skull 2GeoVax Signs HIV/AIDS Vaccine Proposal With Health and Hospital System of Cook County, Illinois 2GeoVax Signs HIV/AIDS Vaccine Proposal With Health and Hospital System of Cook County, Illinois 3GeoVax Signs HIV/AIDS Vaccine Proposal With Health and Hospital System of Cook County, Illinois 4GeoVax Signs HIV/AIDS Vaccine Proposal With Health and Hospital System of Cook County, Illinois 5
... These 2-D standards consist of seven ... inhibitor, bovine carbonic anhydrase, rabbit muscle GAPDH, ... white conalbumin) with pIs ranging from 4.5 ... 17,500 to 76,000. These 2-D standards provide ...
... includes 2 tube gel adaptors, 24 ... length), gaskets, grommets, stoppers. The PROTEAN II ... cell offer the versatility to perform a ... second-dimension 2-D electrophoresis, native, preparative, and gradient ...
The PROTEAN II xi multi-cell 2-D conversion kit converts the PROTEAN II xi multi-cell to the PROTEAN II XL multi-cell for a wider format cell that accepts 17 to 18 cm IPG strips....
StemSep Anti-Phycoertherin Tetrameric Antibody Complexes, 2 mL for labeling 1x10 9 cells. Cross-linking Reagent for StemSep Separations of Cells Labeled with PE-conjugated Antibody....
Biology Products: